4-Fluorophenyl compounds

Vanoxerine is an investigational drug which is being evaluated for the treatment of heart arrhythmias and cocaine dependence. Vanoxerine is a piperazine derivative which has multiple pharmacological activities including acting as an dopamine reuptake inhibitor, serotonin transporter inhibitor, and as a blocker of the cardiac hERG repolarizing potassium channel (IKr).

Monatepil is a calcium channel blocker and α1-adrenergic receptor antagonist used as an antihypertensive.

FGIN-1-27 is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO. It is thought to produce anxiolytic effects by stimulating steroidogenesis of neuroactive steroids such as allopregnanolone.

chemical compound

Fluproquazone (trade name Tormosyl, RF 46-790 ) was a quinazolinone derivative with potent analgesic, antipyretic, and anti-inflammatory effects discovered by Sandoz. It was withdrawn during development due to liver toxicity.

Setoperone (; ; developmental code name R-52245) is a compound that is a ligand to the 5-HT2A receptor. It can be radiolabeled with the radioisotope fluorine-18 and used as a radioligand with positron emission tomography (PET). Several research studies have used the radiolabeled setoperone in neuroimaging for the studying neuropsychiatric disorders, such as depression or schizophrenia. The drug was first described by at least 1984.

chemical compound

Flusoxolol is a selective beta-1 receptor blocker.

Clopimozide (R-29,764) is a typical antipsychotic drug of the diphenylbutylpiperidine class. It is very potent and has an extremely long duration of action, lasting at least one week with a single dose. It was developed by Janssen Pharmaceutica but was never marketed. == See also == Typical antipsychotic Diphenylbutylpiperidine

Lenperone (Elanone-V) is a typical antipsychotic of the butyrophenone chemical class. It was first reported as an anti-emetic in 1974, and its use in treatment of acute schizophrenia was reported in 1975. Related early antipsychotic agents include declenperone and milenperone.

Parafluorofentanyl (4-fluorofentanyl, '''para-fluorofentanyl, pFF''') is an opioid analgesic analogue of fentanyl developed by Janssen Pharmaceuticals in the 1960s.

Senicapoc (ICA-17043) is a Gardos channel blocker.

Aceperone is a neuroleptic drug of the butyrophenone class. It is an α-noradrenergic blocking drug developed by Janssen Pharmaceutica in the 1960s.

Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion which is used for the treatment of gastritis. It acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in South Korea, but is not approved in Europe or the United States.

Difluoropine (O-620) is a stimulant drug synthesised from tropinone, which acts as a potent and selective dopamine reuptake inhibitor. Difluoropine is unique among the tropane-derived dopamine reuptake inhibitors in that the active stereoisomer is the (S) enantiomer rather than the (R) enantiomer, the opposite way round compared to natural cocaine. It is structurally related to benztropine and has similar anticholinergic and antihistamine effects in addition to its dopamine reuptake inhibitory action.

'''N-Methylspiperone (NMSP''') is a derivate of spiperone that is used to study the dopamine and serotonin neurotransmitter systems. Labeled with the radioisotope carbon-11, it can be used for positron emission tomography.

Unifiram (developmental code name DM-232) is an experimental drug. that has antiamnesic and other effects in animal studies with far greater potency than piracetam. A number of related compounds are known, such as sunifiram (DM-235) and sapunifiram (MN-19). Unifiram has two enantiomers, with the dextro form being the more active isomer. It has been shown to reduce the duration of hypnosis induced by pentobarbital, without impairing motor coordination. , no formal human studies with unifiram have been conducted. Unifiram is not patented and, despite the lack of human and long-term toxicity stud

Fluanisone is a typical antipsychotic and sedative of the butyrophenone chemical class. It is used in the treatment of schizophrenia and mania. It is also a component (along with fentanyl) of the injectable veterinary formulation fentanyl/fluanisone (Hypnorm) where it is used for rodent analgesia during short surgical procedures.

Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease. It acts as a COX-2 inhibitor.

Amperozide is an atypical antipsychotic of the diphenylbutylpiperazine class which acts as an antagonist at the 5-HT2A receptor. It does not block dopamine receptors as with most antipsychotic drugs, but does inhibit dopamine release, and alters the firing pattern of dopaminergic neurons. It was investigated for the treatment of schizophrenia in humans, but never adopted clinically. Its main use is instead in veterinary medicine, primarily in intensively farmed pigs, for decreasing aggression and stress and thereby increasing feeding and productivity. ==See also== FG-5893 == References ==

Didesmethylcitalopram is an active metabolite of the antidepressant drug citalopram (racemic). 'Didesmethylescitalopram' is an active metabolite of the antidepressant escitalopram, the S-enantiomer of citalopram. Like citalopram and escitalopram, didesmethyl(es)citalopram functions as a selective serotonin reuptake inhibitor (SSRI), and is responsible for some of its parents' therapeutic benefits.

'''para-Fluorophenylpiperazine (pFPP, 4-FPP, 4-Fluorophenylpiperazine; Fluoperazine, Flipiperazine''') is a piperazine derivative with mildly psychedelic and euphoriant effects. It has been sold as an ingredient in legal recreational drugs known as "Party pills", initially in New Zealand and subsequently in other countries around the world.

Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action. Lidoflazine was discovered at Janssen Pharmaceutica in 1964. In 2025 Lidoflazine has also been reported to interact with tubulin and inhibit its polymerization.

4-Fluoromethamphetamine (4-FMA) is a stimulant drug related to methamphetamine and 4-fluoroamphetamine. It has been reported to be sold as a designer drug, but little is known about its pharmacology or toxicology.

'3β-(p-Fluorobenzoyloxy)tropane, (8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 4-fluorobenzoic acid ester, 4-fluorotropacocaine, 3-Pseudotropyl-4-fluorobenzoate, 3-pseudotropyl-4-fluorobenzoate, pFBT') is a tropane derivative drug which acts as a local anaesthetic, having around 30% the stimulant potency of cocaine but around the same potency as a local anaesthetic. It has been investigated as a potential radiolabelled agent for studying receptor binding, but was not adopted for this application. The main application for fluorotropacocaine, however, has been as a designer drug analogue of cocaine, fir

Flufenacet is an oxyacetanilide herbicide applied before crops have emerged. It was registered for use in the United States in 1998 and the European Union in 2004.

Fladrafinil (developmental code name CRL-40,941), also known as fluorafinil or as bisfluoroadrafinil, is a wakefulness-promoting agent related to modafinil that was never marketed. It is sold online and used non-medically as a nootropic (cognitive enhancer).